stella
beta
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia — Stella
Recruiting
Back to Chronic Immune Thrombocytopenia trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(6 sites)
China
North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei
Henan Cancer Hospital, Zhengzhou, Henan
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi
Qilu Hospital of Shandong University, Jinan, Shandong
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality
Show all 6 locations
View full record on ClinicalTrials.gov